New leukemia agent paves way for transplants

A new treatment option for treating T-cell lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) is on the horizon. In 2006, GlaxoSmithKline will begin marketing the recently approved nelarabine (Arranon), a water-soluble pro-drug of the cytotoxic deoxyguanosine analog 9-beta-D-ar...

Full description

Saved in:
Bibliographic Details
Published in:Drug Topics 2005-12, Vol.149 (23), p.20
Main Author: Kelly Dowhower Karpa
Format: Magazinearticle
Language:English
Subjects:
Drug therapy
Leukemia
Lymphoma
Medical treatment
Pharmaceuticals
Stem cells
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 23
container_start_page 20
container_title Drug Topics
container_volume 149
creator Kelly Dowhower Karpa
description A new treatment option for treating T-cell lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) is on the horizon. In 2006, GlaxoSmithKline will begin marketing the recently approved nelarabine (Arranon), a water-soluble pro-drug of the cytotoxic deoxyguanosine analog 9-beta-D-arabinofuranosylguanine (ara-G). Acute lymphoblastic leukemia (ALL), an aggressive cancer of the white blood cells, affects children more often than adults. ALL accounts for 23% of all cancer diagnoses in children under 15 years of age. Each year, 2,400 children and 1,200 adults are diagnosed with ALL in the United States. There are several forms of ALL. The T-cell immunophenotype (T-ALL) represents a minority of the overall ALL population but has a particularly poor prognosis.
format magazinearticle
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_reports_205052524</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>956373651</sourcerecordid><originalsourceid>FETCH-LOGICAL-p96t-58aa4c3dffa02aae1c9d90d7507c62cdbe93905b1b79c62a9ed39d2ac35675dc3</originalsourceid><addsrcrecordid>eNotzM1KAzEUQOEgFhyr7xD3Bm6SuUmzlOIflLrpvtxJ7hR1nImT1OLbK-jqwLc4Z6LRwXq10ujPRQOgjXJOuwtxWcobALQOfSNut3ySAx_f-eOVJB14rDLTFxd5om_ZT7OsM40lDzTWciUWPQ2Fr_-7FLuH-936SW1eHp_XdxuVg6sKV0RttKnvCQwR6xhSgOQRfHQmpo6DDYCd7nz4BQqcbEiGokXnMUW7FDd_2zxPn0cudT9znuZa9gYQ0KBp7Q9CFj7w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>magazinearticle</recordtype><pqid>205052524</pqid></control><display><type>magazinearticle</type><title>New leukemia agent paves way for transplants</title><source>Business Source Ultimate</source><creator>Kelly Dowhower Karpa</creator><creatorcontrib>Kelly Dowhower Karpa</creatorcontrib><description>A new treatment option for treating T-cell lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) is on the horizon. In 2006, GlaxoSmithKline will begin marketing the recently approved nelarabine (Arranon), a water-soluble pro-drug of the cytotoxic deoxyguanosine analog 9-beta-D-arabinofuranosylguanine (ara-G). Acute lymphoblastic leukemia (ALL), an aggressive cancer of the white blood cells, affects children more often than adults. ALL accounts for 23% of all cancer diagnoses in children under 15 years of age. Each year, 2,400 children and 1,200 adults are diagnosed with ALL in the United States. There are several forms of ALL. The T-cell immunophenotype (T-ALL) represents a minority of the overall ALL population but has a particularly poor prognosis.</description><identifier>ISSN: 0012-6616</identifier><identifier>EISSN: 1937-8157</identifier><identifier>CODEN: DGTNA7</identifier><language>eng</language><publisher>Monmouth Junction: MultiMedia Healthcare Inc</publisher><subject>Drug therapy ; Leukemia ; Lymphoma ; Medical treatment ; Pharmaceuticals ; Stem cells</subject><ispartof>Drug Topics, 2005-12, Vol.149 (23), p.20</ispartof><rights>Copyright Medical Economics Inc. Dec 12, 2005</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>312,780,784,791</link.rule.ids></links><search><creatorcontrib>Kelly Dowhower Karpa</creatorcontrib><title>New leukemia agent paves way for transplants</title><title>Drug Topics</title><description>A new treatment option for treating T-cell lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) is on the horizon. In 2006, GlaxoSmithKline will begin marketing the recently approved nelarabine (Arranon), a water-soluble pro-drug of the cytotoxic deoxyguanosine analog 9-beta-D-arabinofuranosylguanine (ara-G). Acute lymphoblastic leukemia (ALL), an aggressive cancer of the white blood cells, affects children more often than adults. ALL accounts for 23% of all cancer diagnoses in children under 15 years of age. Each year, 2,400 children and 1,200 adults are diagnosed with ALL in the United States. There are several forms of ALL. The T-cell immunophenotype (T-ALL) represents a minority of the overall ALL population but has a particularly poor prognosis.</description><subject>Drug therapy</subject><subject>Leukemia</subject><subject>Lymphoma</subject><subject>Medical treatment</subject><subject>Pharmaceuticals</subject><subject>Stem cells</subject><issn>0012-6616</issn><issn>1937-8157</issn><fulltext>true</fulltext><rsrctype>magazinearticle</rsrctype><creationdate>2005</creationdate><recordtype>magazinearticle</recordtype><recordid>eNotzM1KAzEUQOEgFhyr7xD3Bm6SuUmzlOIflLrpvtxJ7hR1nImT1OLbK-jqwLc4Z6LRwXq10ujPRQOgjXJOuwtxWcobALQOfSNut3ySAx_f-eOVJB14rDLTFxd5om_ZT7OsM40lDzTWciUWPQ2Fr_-7FLuH-936SW1eHp_XdxuVg6sKV0RttKnvCQwR6xhSgOQRfHQmpo6DDYCd7nz4BQqcbEiGokXnMUW7FDd_2zxPn0cudT9znuZa9gYQ0KBp7Q9CFj7w</recordid><startdate>20051212</startdate><enddate>20051212</enddate><creator>Kelly Dowhower Karpa</creator><general>MultiMedia Healthcare Inc</general><scope>K9.</scope><scope>U9A</scope></search><sort><creationdate>20051212</creationdate><title>New leukemia agent paves way for transplants</title><author>Kelly Dowhower Karpa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p96t-58aa4c3dffa02aae1c9d90d7507c62cdbe93905b1b79c62a9ed39d2ac35675dc3</frbrgroupid><rsrctype>magazinearticle</rsrctype><prefilter>magazinearticle</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Drug therapy</topic><topic>Leukemia</topic><topic>Lymphoma</topic><topic>Medical treatment</topic><topic>Pharmaceuticals</topic><topic>Stem cells</topic><toplevel>online_resources</toplevel><creatorcontrib>Kelly Dowhower Karpa</creatorcontrib><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>Drug Topics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kelly Dowhower Karpa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New leukemia agent paves way for transplants</atitle><jtitle>Drug Topics</jtitle><date>2005-12-12</date><risdate>2005</risdate><volume>149</volume><issue>23</issue><spage>20</spage><pages>20-</pages><issn>0012-6616</issn><eissn>1937-8157</eissn><coden>DGTNA7</coden><abstract>A new treatment option for treating T-cell lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) is on the horizon. In 2006, GlaxoSmithKline will begin marketing the recently approved nelarabine (Arranon), a water-soluble pro-drug of the cytotoxic deoxyguanosine analog 9-beta-D-arabinofuranosylguanine (ara-G). Acute lymphoblastic leukemia (ALL), an aggressive cancer of the white blood cells, affects children more often than adults. ALL accounts for 23% of all cancer diagnoses in children under 15 years of age. Each year, 2,400 children and 1,200 adults are diagnosed with ALL in the United States. There are several forms of ALL. The T-cell immunophenotype (T-ALL) represents a minority of the overall ALL population but has a particularly poor prognosis.</abstract><cop>Monmouth Junction</cop><pub>MultiMedia Healthcare Inc</pub></addata></record>
fulltext fulltext
identifier ISSN: 0012-6616
ispartof Drug Topics, 2005-12, Vol.149 (23), p.20
issn 0012-6616
1937-8157
language eng
recordid cdi_proquest_reports_205052524
source Business Source Ultimate
subjects Drug therapy
Leukemia
Lymphoma
Medical treatment
Pharmaceuticals
Stem cells
title New leukemia agent paves way for transplants
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T16%3A58%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20leukemia%20agent%20paves%20way%20for%20transplants&rft.jtitle=Drug%20Topics&rft.au=Kelly%20Dowhower%20Karpa&rft.date=2005-12-12&rft.volume=149&rft.issue=23&rft.spage=20&rft.pages=20-&rft.issn=0012-6616&rft.eissn=1937-8157&rft.coden=DGTNA7&rft_id=info:doi/&rft_dat=%3Cproquest%3E956373651%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p96t-58aa4c3dffa02aae1c9d90d7507c62cdbe93905b1b79c62a9ed39d2ac35675dc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=205052524&rft_id=info:pmid/&rfr_iscdi=true